Stock Price

1,60 EUR

-345.95% ROA

147.15% ROE

-1.15x PER

Market Cap.

394.954,00 EUR

-92.47% DER

0% Yield

-2861.58% NPM

Poxel S.A. Stock Analysis

Poxel S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Poxel S.A. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Poxel S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Poxel S.A. Technical Stock Analysis
# Analysis Recommendation

Poxel S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Poxel S.A. Revenue
Year Revenue Growth
2012 0
2013 0 0%
2014 0 0%
2015 59.650 100%
2016 70.265 15.11%
2017 5.290.000 98.67%
2018 62.381.000 91.52%
2019 26.557.000 -134.89%
2020 6.806.000 -290.2%
2021 13.397.000 49.2%
2022 674.000 -1887.69%
2023 1.910.000 64.71%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Poxel S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2012 8.698.535
2013 9.081.634 4.22%
2014 6.996.109 -29.81%
2015 9.237.820 24.27%
2016 20.921.948 55.85%
2017 24.096.000 13.17%
2018 58.092.000 58.52%
2019 44.550.000 -30.4%
2020 29.219.000 -52.47%
2021 27.479.000 -6.33%
2022 13.940.000 -97.12%
2023 38.688.000 63.97%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Poxel S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 914.904
2013 1.078.077 15.14%
2014 1.813.107 40.54%
2015 3.868.033 53.13%
2016 5.577.870 30.65%
2017 6.219.000 10.31%
2018 7.527.000 17.38%
2019 11.051.000 31.89%
2020 9.923.000 -11.37%
2021 10.627.000 6.62%
2022 9.443.000 -12.54%
2023 8.556.000 -10.37%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Poxel S.A. EBITDA
Year EBITDA Growth
2012 -7.104.940
2013 -7.259.072 2.12%
2014 -6.883.925 -5.45%
2015 -11.314.053 39.16%
2016 -23.150.592 51.13%
2017 -21.865.000 -5.88%
2018 374.000 5946.26%
2019 -24.593.000 101.52%
2020 -29.715.000 17.24%
2021 -22.358.000 -32.91%
2022 -21.795.000 -2.58%
2023 -45.878.000 52.49%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Poxel S.A. Gross Profit
Year Gross Profit Growth
2012 -16.915
2013 -15.602 -8.42%
2014 -23.211 32.78%
2015 34.462 167.35%
2016 70.265 50.95%
2017 5.290.000 98.67%
2018 62.381.000 91.52%
2019 26.557.000 -134.89%
2020 6.806.000 -290.2%
2021 13.338.000 48.97%
2022 2.000 -666800%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Poxel S.A. Net Profit
Year Net Profit Growth
2012 -7.138.342
2013 -20.452.697 65.1%
2014 -14.082.448 -45.24%
2015 -12.241.013 -15.04%
2016 -24.482.934 50%
2017 -22.298.000 -9.8%
2018 1.301.000 1813.91%
2019 -25.743.000 105.05%
2020 -31.831.000 19.13%
2021 -23.763.000 -33.95%
2022 -31.398.000 24.32%
2023 -52.486.000 40.18%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Poxel S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -1
2013 -3 100%
2014 -1 -100%
2015 -1 0%
2016 -1 100%
2017 -1 0%
2018 0 0%
2019 -1 0%
2020 -1 100%
2021 -1 0%
2022 -1 100%
2023 -2 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Poxel S.A. Free Cashflow
Year Free Cashflow Growth
2012 -5.650.111
2013 -6.694.612 15.6%
2014 -6.102.175 -9.71%
2015 -10.204.510 40.2%
2016 -18.873.217 45.93%
2017 8.089.999 333.29%
2018 -4.957.000 263.2%
2019 -25.766.000 80.76%
2020 -25.984.000 0.84%
2021 -16.921.000 -53.56%
2022 -21.824.000 22.47%
2023 -3.920.500 -456.66%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Poxel S.A. Operating Cashflow
Year Operating Cashflow Growth
2012 -5.642.745
2013 -6.692.421 15.68%
2014 -6.089.349 -9.9%
2015 -10.061.267 39.48%
2016 -18.848.822 46.62%
2017 8.125.999 331.96%
2018 -4.744.000 271.29%
2019 -25.693.000 81.54%
2020 -25.749.000 0.22%
2021 -16.893.000 -52.42%
2022 -21.813.000 22.56%
2023 -3.920.500 -456.38%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Poxel S.A. Capital Expenditure
Year Capital Expenditure Growth
2012 7.366
2013 2.191 -236.19%
2014 12.826 82.92%
2015 143.243 91.05%
2016 24.395 -487.18%
2017 36.000 32.24%
2018 213.000 83.1%
2019 73.000 -191.78%
2020 235.000 68.94%
2021 28.000 -739.29%
2022 11.000 -154.55%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Poxel S.A. Equity
Year Equity Growth
2012 315.030
2013 -20.010.221 101.57%
2014 -2.547.504 -685.48%
2015 38.027.817 106.7%
2016 39.385.488 3.45%
2017 19.327.000 -103.78%
2018 62.432.000 69.04%
2019 39.142.000 -59.5%
2020 27.065.000 -44.62%
2021 8.205.999 -229.82%
2022 -18.241.000 144.99%
2023 -41.887.000 56.45%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Poxel S.A. Assets
Year Assets Growth
2012 8.182.921
2013 12.265.799 33.29%
2014 13.825.899 11.28%
2015 46.848.112 70.49%
2016 50.303.785 6.87%
2017 66.751.999 24.64%
2018 105.516.000 36.74%
2019 72.302.000 -45.94%
2020 65.077.000 -11.1%
2021 54.889.000 -18.56%
2022 34.714.000 -58.12%
2023 12.807.000 -171.05%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Poxel S.A. Liabilities
Year Liabilities Growth
2012 7.867.891
2013 32.276.020 75.62%
2014 16.373.403 -97.12%
2015 8.820.295 -85.63%
2016 10.918.297 19.22%
2017 47.425.000 76.98%
2018 43.084.000 -10.08%
2019 33.159.999 -29.93%
2020 38.012.000 12.76%
2021 46.683.000 18.57%
2022 52.955.000 11.84%
2023 54.694.000 3.18%

Poxel S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.05
Net Income per Share
-1.39
Price to Earning Ratio
-1.15x
Price To Sales Ratio
0.26x
POCF Ratio
-3.11
PFCF Ratio
-0.02
Price to Book Ratio
-1.21
EV to Sales
-4.66
EV Over EBITDA
0.22
EV to Operating CashFlow
0.44
EV to FreeCashFlow
0.44
Earnings Yield
-0.87
FreeCashFlow Yield
-41.41
Market Cap
0,00 Bil.
Enterprise Value
-0,01 Bil.
Graham Number
6.43
Graham NetNet
-1.45

Income Statement Metrics

Net Income per Share
-1.39
Income Quality
0.37
ROE
1.47
Return On Assets
-3.45
Return On Capital Employed
13.66
Net Income per EBT
1
EBT Per Ebit
1.34
Ebit per Revenue
-21.34
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
6.1
Research & Developement to Revenue
15.83
Stock Based Compensation to Revenue
0.72
Gross Profit Margin
0
Operating Profit Margin
-21.34
Pretax Profit Margin
-28.61
Net Profit Margin
-28.62

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.52
Free CashFlow per Share
-0.52
Capex to Operating CashFlow
0
Capex to Revenue
-0
Capex to Depreciation
-0.01
Return on Invested Capital
10.46
Return on Tangible Assets
-3.46
Days Sales Outstanding
328.64
Days Payables Outstanding
1052.45
Days of Inventory on Hand
0
Receivables Turnover
1.11
Payables Turnover
0.35
Inventory Turnover
1544000
Capex per Share
-0

Balance Sheet

Cash per Share
0,24
Book Value per Share
-1,32
Tangible Book Value per Share
-1.32
Shareholders Equity per Share
-1.32
Interest Debt per Share
1.22
Debt to Equity
-0.92
Debt to Assets
3.02
Net Debt to EBITDA
0.23
Current Ratio
0.77
Tangible Asset Value
-0,04 Bil.
Net Current Asset Value
-0,04 Bil.
Invested Capital
-0.92
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
1
Debt to Market Cap
98.07

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Poxel S.A. Dividends
Year Dividends Growth

Poxel S.A. Profile

About Poxel S.A.

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). Poxel S.A. has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. The company was incorporated in 2009 and is headquartered in Lyon, France.

CEO
Mr. Thomas Kuhn M.B.A., Pharm
Employee
15
Address
Immeuble Le Sunway
Lyon, 69007

Poxel S.A. Executives & BODs

Poxel S.A. Executives & BODs
# Name Age
1 Mr. Quentin Durand
Executive Vice President, Chief Legal Officer & Head of Corporate Social Responsibility
70
2 Dr. Pascale Fouqueray-Grellier M.D., Ph.D.
Co-Founder and Executive Vice President of Clinical Development & Regulatory Affairs
70
3 Dr. Sophie Hallakou-Bozec Ph.D.
Co-Founder and Executive Vice President of R&D Pharmacology & Scientific Communication
70
4 Ms. Sylvie Bertrand
Vice President of Human Resources
70
5 Arthur Rouille
Investor Relations Officer
70
6 Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D.
Co-Founder, Chief Executive Officer & Director
70
7 Dr. Sébastien Bolze Ph.D., Pharm D Ph.D., Pharm.D.
Co-Founder, Chief Operating Officer and Executive Vice President of Project Management, Non Clinical & Manufacturing Operations
70

Poxel S.A. Competitors